

Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8
28022 – Madrid
España
(Reference Member State)

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

**TULAJECT 100 mg/ml SOLUTION FOR INJECTION FOR
CATTLE, PIGS AND SHEEP**

CORREO ELECTRÓNICO

mresvet@aemps.es

15026 Tulaject 100 - ES V 0373 001 DC - PuAR 21 07 22 (002)

F-DMV-25-06

C/ CAMPEZO, 1 – EDIFICIO 8
28022 MADRID
TEL: 91 822 54 01
FAX: 91 822 5443



MODULE 1

PRODUCT SUMMARY

| | |
|--|--|
| EU Procedure number | ES/V/0373/001/DC |
| Name, strength and pharmaceutical form | Tulaject 100 mg/ml solution for injection for cattle, pigs and sheep |
| Applicant | Alivira Animal Health Limited 16 Glenoaks Close Glencorner |
| Active substance(s) | Tulathromycin |
| ATC Vetcode | QJ01FA94 |
| Target species | Cattle, pigs and sheep |
| Indication for use | <p><u>Cattle</u> Treatment and metaphylaxis of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis susceptible to tulathromycin. The presence of the disease in the group must be established before the product is used.</p> <p>Treatment of infectious bovine keratoconjunctivitis (IBK) associated with Moraxella bovis susceptible to tulathromycin.</p> <p><u>Pigs</u> Treatment and metaphylaxis of swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Mycoplasma hyopneumoniae, Haemophilus parasuis and Bordetella bronchiseptica susceptible to tulathromycin. The presence of the disease in the group must be established before the product is used. The veterinary medicinal product should only be used if pigs are expected to develop the disease within 2–3 days.</p> <p><u>Sheep</u> Treatment of the early stages of infectious pododermatitis (foot rot) associated with virulent Dichelobacter nodosus requiring systemic treatment.</p> |



Tulaject 100 mg/ml solution for injection for cattle, pigs and sheep
Alivira Animal Health Limited
Date: 21/07/22

<ES/V/nnnn/sss/MR or DC>
Application for Decentralised Procedure
Publicly available assessment report

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (<http://www.hma.eu>).



MODULE 3

PUBLIC ASSESSMENT REPORT

| | |
|--|---|
| Legal basis of original application | Decentralised application in accordance with Article 13.1 of Directive 2001/82/EC as amended. |
| Date of completion of the original decentralised procedure | 23.09.20 |
| Date product first authorised in the ReferenceMemberState (MRP only) | - |
| Concerned Member States for original procedure | BE, CY, EE, FR, DE, EL, RO, HU, LV, NL, IT, PL, PT, LT |

I. SCIENTIFIC OVERVIEW

For public assessment reports for the first authorisation in a range:

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC. The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. *Qualitative and quantitative particulars*

The product contains tulathromycin (100 mg/ml) as active substance, monothioglycerol as antioxidant and the excipients citric acid, propylene glycol, hydrochloric acid solution (10%), sodium hydroxide and water for injections. The product is a clear colorless to pale yellow colored solution, free from visible particles.

The veterinary medicinal product is presented in clear glass (type I Ph. Eur.) vials of 50 ml, 100 ml and 250 ml closed with a chlorobutyl rubber stopper and sealed with an aluminium cap.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. *Method of Preparation of the Product*

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. *Control of Starting Materials*

The active substance is tulathromycin, an established active substance which is not described in a pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The information on the active substance is provided according to the Active Substance Master File (ASMF) procedure.

Confirmation is provided regarding compliance of the finished product with the current Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products.

D. *Control on intermediate products*

Not applicable.

E. *Control Tests on the Finished Product*



The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance tulathromycin have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life (3 years) when stored under the approved conditions.

Data submitted on in-use stability studies are considered sufficient to support an in-use shelf life of 28 days after broaching.

G. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

As this is a generic application according to Article 13 and bioequivalence with the reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to the reference product.

Toxicological Studies

As this is a generic application according to Article 13 and bioequivalence with the reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

User Safety

Although this is a generic application according to Article 13 and bioequivalence with the reference product has been demonstrated, the applicant has provided a brief user safety assessment broadly in accordance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because in all scenarios the initial predicted environmental concentrations in soil are less than 100 µg/kg.

III.B Residues documentation

Residue Studies

No residue depletion studies were conducted because bioequivalence to the reference product has been demonstrated and there are no differences in the composition of the candidate product when compared to the reference product.

MRLs

The active substance Tulathromycin is an allowed substance as described in table 1 of the annex to Commission Regulation (EU) No 37/2010.

MRLs are listed below:

| | Porcine | Bovine | Ovine Caprine |
|------------|---|------------|------------------|
| Muscle | 800 µg/kg | 300 µg/kg | 450 µg/kg |
| Liver | 4000 µg/kg | 4500 µg/kg | 5400 µg/kg |
| Kidney | 8000 µg/kg | 3000 µg/kg | 1800 µg/kg |
| Fat / skin | 300 µg/kg | 200 µg/kg | 250 µg/kg |
| Milk | Not for use in animals from which milk is produced for human consumption. | | |

Withdrawal Periods

Based on the data provided above, a withdrawal period of 22 days for meat and offal in cattle, 13 days for meat and offal in pigs and 16 days for meat and offal in sheep are justified. The product is not authorised for use in animals producing milk for human consumption.



IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

IV.A Pre-Clinical Studies

Resistance

Based on the available updated information, the resistance status is considered to be sufficiently documented.

Adequate warnings and precautions appear on the product literature.



V . OVERALL CONCLUSION AND BENEFIT- RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.



MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Quality changes

| Summary of change (Application number) | Section updated in Module 3 | Approval date |
|---|-----------------------------------|-----------------------------|
| C.I.2.a - SAFETY, EFFICACY, PHARMACOVIGILANCE CHANGES - HUMAN AND VETERINARY MEDICINAL PRODUCTS - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - Implementation of change(s) for which no new additional data is required to be submitted by the MAH | N/A | 14 th July 2021 |
| B.II.d.2.d - QUALITY CHANGES - FINISHED PRODUCT - Control of finished product - Change in test procedure for the finished product - Other changes to a test procedure (including replacement (IB) | N/A | 25 th April 2022 |